FDA clearance doesn’t guarantee payer coverage. Cardiovascular AI companies often find that Medicare and commercial payers evaluate new technologies using a very different set of questions before agreeing to reimburse them.

This webinar brings together leaders from the payer, healthcare operator, and value-based cardiology perspectives to discuss what it truly takes to build a compelling reimbursement case, and what cardiovascular AI companies should prepare for as they pursue coverage and adoption.

In this webinar, we’ll cover:

• What Medicare and commercial payers require before covering AI-driven cardiovascular tools
• How value-based and risk-based payment structures, like contracts tied to heart-failure readmission rates, offer a path around the traditional reimbursement bottleneck
• The key decisions and common missteps that most often derail reimbursement for cardiovascular AI companies specifically
• Concrete, actionable steps a cardiovascular AI founder can take today to get ahead on reimbursement